<DOC>
	<DOCNO>NCT00165776</DOCNO>
	<brief_summary>To evaluate efficacy safety E2014 ( 2500U , 5000U , 10000U , placebo ) multicenter , randomize , double-blind , parallel group comparative study intramuscularly administer patient spasmodic torticollis . Primary endpoint efficacy evaluation change TWSTRS total score baseline measure Week 4 clinical recommend dose examine Williams multiple comparison . For safety evaluation , inter group comparison ( active drug placebo ) perform mainly focus incidence adverse event , adverse drug reaction , abnormal change laboratory parameter .</brief_summary>
	<brief_title>Randomized , Double-Blind , Placebo-Controlled , Parallel , Group Dose-Response , Study E2014 Patients WIth Spasmodic Torticollis</brief_title>
	<detailed_description />
	<mesh_term>Dystonia</mesh_term>
	<mesh_term>Torticollis</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<mesh_term>rimabotulinumtoxinB</mesh_term>
	<criteria>Patients give write informed consent age great equal 20 year less 75 year time obtain prior consent ( irrespective gender ) . Patients dystonic symptom least 2 lesion follow cervical muscle . Sternocleidomastoid Scalenus complex ( scalenus anterior , scalenus medius , scalenus posterior ) Trapezius Levator scapulae Splenius capitis Semispinalis capitis Patients persistently symptoms ( 2 ) 1 year longer . Patients weigh great equal 40 kg . Patients whose TWSTRS total score baseline great equal 20 . Patients whose TWSTRSseverity score baseline great equal 10 . Patients whose TWSTRSdisability score baseline great equal 3 . Patients whose TWSTRSpain score baseline great equal 1 . Patients judge eligible study entry investigator subinvestigator base physical neurological finding , laboratory parameter , ECG result . Patients botulinum toxinresistant previous exposure ( primary noresponder* ) *If patient responder botulinum toxin treatment thereafter become nonresponder include study . Patients whose passive range motion neck significantly narrow due cervical contracture spondylosis . Patients pure retrocollis anterocollisassociated symptom . Patients receive botulinum toxin agent within 4 month prior study treatment E2014 , show carryover effect previous treatment botulinum toxin time start study administration even though previous treatment give 4 month earlier . Patients treat narcotic antibiotic may potentiate effect muscle relaxation ( spectinomycin hydrochloride preparation , aminoglycosides , polypeptide , tetracycline , lincomycin ) within 4 month prior study treatment . Patients start alter dose level follow agent ( musculoskeletal relaxant , antispasm drug , strong tranquilizer , benzodiazepine include similar drug , anticholinergic drug , antiparkinsonian drug , antidepressant ) within 4 week prior study treatment . Patients receive medical care ( ) pharmacotherapies ( surgical intervention , MAB , acupuncture , relaxation , etc . ) prior study treatment show carryover effect care unstable condition time start study treatment . Patients history myectomy neurectomy neck and/or shoulder . Patients history hypersensitivity E2014 's ingredient ( botulinum toxin type B , human serum albumin , sodium succinate buffer solution ) , type botulinum toxin . Patients complication ( ) history serious neurological musculoskeletal disease ( myasthenia , amyotrophic lateral sclerosis , etc . ) , cardiovascular disease ( acute myocardial infarction , etc . ) , respiratory disease ( COPD , etc . ) , renal disease ( acute chronic renal failure , etc . ) , hepatic disease ( cirrhosis , etc . ) , gastrointestinal disease ( paralytic ileus , etc . ) , dermatological disease ( toxic epidermal necrosis , etc . ) , psychiatric disease ( schizophrenia , alcohol drug dependence , etc . ) , hematological disease ( aplastic anemia , etc . ) , and/or infectious disease ( hepatitis , syphilis , AIDS , etc. ) . Patients complication history malignant tumor ( ) . Patients participate another clinical study within 30 day prior obtain inform consent study . Women pregnant , childbearing potential , childbearing intension study period , lactate . Others judge ineligible study entry investigator subinvestigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>